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Introduction
Nanoparticles are materials with overall dimensions in the nanoscale, ie, under 100 nm. 
In recent years, these materials have emerged as important players in modern medi-
cine, with applications ranging from contrast agents in medical imaging to carriers 
for gene delivery into individual cells. Nanoparticles have a number of properties that 
distinguish them from bulk materials simply by virtue of their size, such as chemical 
reactivity, energy absorption, and biological mobility.
Nanoparticles are also referred to as “zero-dimensional” nanomaterials. This deﬁ  ni-
tion arises from the fact that all of their dimensions are in the nanoscale, as opposed to 
one-dimensional nanomaterials, which have one dimension larger than the nanoscale 
(such as nanowires and nanotubes), and two-dimensional nanomaterials, which have 
two dimensions larger than the nanoscale (such as self-assembled monolayer ﬁ  lms).
The beneﬁ  ts of nanoparticles to modern medicine are numerous. Indeed there 
are some instances where nanoparticles enable analyses and therapies that simply 
cannot be performed otherwise. However, nanoparticles also bring with them unique 
environmental and societal challenges, particularly in regard to toxicity. This review 
aims to highlight the major contributions of nanoparticles to modern medicine and 
also discuss environmental and societal aspects of their use. 
This review is intended to serve as a broad introduction to the role of nanoparticles 
in medicine rather than as an exhaustive review. Furthermore, this review will focus 
on technologies that have either already advanced to clinical use or in vivo experi-
mentation. Within the broad categories of medical imaging and drug/gene delivery, 
this review will discuss examples of medical applications of nanoparticles. Where 
possible, the reader will be referred to the numerous comprehensive reviews already 
available within each application area. Lastly, the environmental and societal impact 
of the use of nanoparticles in modern medicine will also be discussed.International Journal of Nanomedicine 2007:2(2) 130
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Nanoparticles in medical imaging
Nanoparticles can provide significant improvements in 
traditional biological imaging of cells and tissues using 
ﬂ  uorescence microscopy as well as in modern magnetic 
resonance imaging (MRI) of various regions of the body. 
Chemical composition distinguishes the nanoparticles used 
in these two techniques. A summary of the applications of 
nanoparticles in imaging is provided in Table 1
Optical imaging 
Conventional imaging of cells and tissue sections is per-
formed by loading organic dyes into the sample. Dyes such 
as ﬂ  uorescein isocyanate (FITC) and rhodamine are often 
tethered to biomolecules that selectively bind to cells or 
cell components through ligand/receptor interactions. Two 
problems often encountered in this mode of imaging are 
inadequate ﬂ  uorescence intensity and photobleaching. Pho-
tobleaching is the gradual decrease in ﬂ  uorescence intensity 
often observed over time due to irreversible changes in the 
molecular structure of the dye molecules that render them 
nonﬂ  uorescent.
Quantum dots (QDs) are nanoparticles composed of 
inorganic semiconductor molecules. These nanoparticles 
emit strong ﬂ  uorescent light under ultraviolet (UV) illumi-
nation, and the wavelength (color) of the ﬂ  uorescent light 
emitted depends sensitively on particle size. This size depen-
dence is a unique characteristic of these materials. Inorganic 
semiconductor molecules derive their properties from the 
presence of a “band gap.” The band gap is the difference in 
energy between the valence band (or energy level), where 
the electrons primarily reside, and the conduction band, to 
which they can be “promoted” by the supply of energy of 
a speciﬁ  c wavelength (excitation), usually in the form of 
a photon. When an electron moves from the valence band 
to the conduction band, it leaves behind a “hole” (this is a 
term given to an energy level lacking an electron, and is 
not a physical feature). When the excitation ceases, elec-
trons move back to the valence band, releasing their excess 
energy. In the case of QDs, this energy is released entirely 
as light. Larger QDs have more electron-hole pairs and are 
therefore capable of absorbing and releasing more energy. 
Since energy is inversely related to wavelength (E = hc/λ), 
this means that the wavelength of emitted light decreases 
as QD size increases. QDs can emit light that is far more 
intense and signiﬁ  cantly more stable against photobleaching 
compared with conventional organic dyes. This is a major 
advantage in 3-D tissue imaging where photobleaching is a 
major concern during acquisition of successive sections in 
the z-direction.
Being inorganic materials, QDs are insoluble in aqueous 
solutions. An essential part of using QDs in biological and 
medical applications is therefore coating them with a thin 
layer of a water-soluble material. Typically, this step is fol-
lowed by coating with a material that binds preferentially to a 
particular cell or cell component. The surface of each QD has 
a large number of sites onto which soluble and/or bioactive 
molecules can be tethered. Furthermore, more than one type 
of molecule can be attached to each QD, giving it multiple 
functionalities. In a review of the application of QDs for live 
cell and in vivo imaging, Michalet and colleagues (2005) 
have described different surface modiﬁ  cation strategies such 
as targeting and prolonged retention in the bloodstream.
Kim and colleagues (2004) recently described the use 
of oligomeric phosphine-coated QDs to map lymph nodes 
in mice and pigs. These QDs were made of CdTe capped 
with CdSe, a combination that is capable of light emission 
under near infrared excitation. The signiﬁ  cance of this work 
is the ability to map lymph nodes up to 1 cm below the skin 
surface without the need for surgical incisions. The toxicity 
of the injected QDs was not examined in this study and the 
authors inferred that the concentrations used were below 
known toxic levels.
QDs can be targeted to speciﬁ  c organs within the body by 
coating the QD surface with appropriate molecules. Akerman 
and colleagues (2002) demonstrated that ZnS-capped CdSe 
QDs can be directed to the lungs of mice by coating the QD 
surface with a peptide sequence, CGFECVRQCPERC, which 
is known to bind to endothelial cells in lung blood vessels. 
The same methodology was used to direct QDs to blood or 
lymphatic vessels within tumors in mice. In both instances, 
the QDs were internalized by the targeted cells by endocytosis 
but not by cells in surrounding tissue.
Gao and colleagues (2004) encapsulated semiconduc-
tor QDs within an amphiphilic copolymer and modiﬁ  ed 
the polymer surface with targeting ligands (as shown in 
Figure 1A). The QDs were made of CdSe capped with ZnS 
and protected from aggregation in solution by a coordinating 
ligand (tri-n-octylphosphine oxide [TOPO]). The copolymer 
was a triblock, consisting of butylacrylate, ethylacrylate, 
and methacrylic acid segments; the former two segment 
types are more hydrophobic than the latter. In solution, the 
hydrophobic segments of the copolymer are attracted to the 
TOPO, resulting in the structure shown in Figure 1A, which 
has the carboxylic acid groups of the hydrophilic segment International Journal of Nanomedicine 2007:2(2) 131
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sticking out. These acid groups can be used as attachment 
points for molecules such as poly(ethylene glycol) (PEG) or 
afﬁ  nity ligands. The composite particles were 20–30 nm in 
diameter. Tumor targeting was achieved by tethering to the 
particle surface an antibody against prostate speciﬁ  c mem-
brane antigen (PSMA). As hypothesized, these particles did 
indeed selectively bind to tumors in mice upon intravenous 
injection (Figure 1B). No accumulation was observed in the 
brain, kidney, or lung.
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is a technique used to 
perform 3-D, noninvasive scans of the body. This technique 
is widely used in modern medicine, particularly in the diag-
nosis and treatment of most diseases of the brain, spine, and 
musculoskeletal system. MRI utilizes magnetic resonance 
spectroscopy to analyze hydrogen atoms that are naturally 
present in tissue (as water and cell membrane proteins, for 
example). A sample is placed within a strong static mag-
netic ﬁ  eld and a transverse radiofrequency (RF) signal is 
use to excite the magnetic dipoles within hydrogen nuclei 
in the sample. Prior to the RF pulse, the spinning nuclei are 
aligned with the static ﬁ  eld. The RF pulse provides additional 
energy to these nuclei and causes them to spin at a different 
frequency and in a different (transverse) direction. Follow-
ing the RF pulse, the hydrogen nuclei return, or “relax,” to 
a state of equilibrium in alignment with the static magnetic 
ﬁ  eld. The relaxation process is typically characterized by two 
parameters referred to as T1 and T2. T1 represents the time 
required for restoration of nuclear spins in alignment with the 
static ﬁ  eld; T2 represents the characteristic time over which 
the transverse magnetization of the nuclei vanishes. Hydro-
gen nuclei and different types of tissue can be differentiated 
on the basis of different T1 and T2 relaxation times. MRI 
scans involve collection of several images based on spatial 
location as well as on weighting based on T1 or T2. A sample 
with low T1 appears bright in a T1-weighted image.
In many clinical applications, however, the natural dif-
ferences in relaxation times between regions of interest 
(such as normal versus scar tissue) are small, necessitating 
the use of contrast agents. Contrast agents are typically 
paramagnetic molecules that can alter the relaxation times 
of selected regions or types of tissue or ﬂ  uid within the body. 
Compounds of gadolinium have been successfully utilized 
for several years as contrast agents with the ability to resolve 
such areas as the kidney and brain (Mornet et al 2004). 
Gadolinium-based contrast agents act by shortening T1. 
Superparamagnetic iron oxide (SPIO) nanoparticles have 
recently emerged as effective contrast agents for T2-weighting, 
thereby serving as a complement to gadolinium-based agents. 
T2 weighting is important for the imaging of the liver, lymph 
nodes, and bone marrow (Mornet et al 2004). The relaxation 
times of superparamagnetic nanoparticles (such as iron oxide) 
are much higher than those of gadolinium-based agents.
Huh and colleagues (2005) recently described how SPIO 
nanoparticles can be used to detect cancer in vivo using a 
mouse xenograft model. In this investigation, the nanopar-
ticles were conjugated to herceptin, a cancer-targeting 
antibody. SPIO nanoparticles were prepared by the thermal 
decomposition of iron acetylacetonate and made water-
soluble by binding with 2, 3-dimercaptosuccinic acid before 
conjugation with herceptin. When administered intravenous-
ly to mice, a rapid change was observed in the T2-weighted 
MRI signal from the tumor located in the thigh of the animals. 
The speciﬁ  city of antibody binding was veriﬁ  ed in a control 
experiment where the same iron oxide nanoparticles were 
OD capping ligand
TOPO
PEG
Polymer coating
Affinity ligands Injection
site
Tumors
B A
Figure 1 Quantum dots (QDs) used in tumor imaging. (A) Surface modiﬁ  cation of the CdSe/ZnS QD with a capping ligand TOPO which keeps QDs from aggregating in 
solution; this assembly is enclosed by an amphiphilic polymer whose hydrophobic segments bind to TOPO and whose hydrophilic carboxylic acid groups can bind to afﬁ  nity 
ligands (such as a tumor-speciﬁ  c antibody) or PEG. (B) Fluorescence image of a live mouse showing targeted delivery of QDs to a tumor.  Adapted from Gao et al (2004) 
with permission from Macmillian Publishers Ltd: Nature Biotechnology. Copyright © 2004.International Journal of Nanomedicine 2007:2(2) 133
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bound to a nonspeciﬁ  c antibody. These control nanoparticles 
did not produce any change in MRI signal.
SPIO nanoparticles can also be used to visualize features 
that would not otherwise be detectable by conventional MRI. 
Harisinghani and colleagues (2003) utilized SPIO nanopar-
ticles in human patients with prostate cancer to detect small 
metastases in the lymph node. In this case, the nanoparticles 
were coated with dextran for retention in the blood stream 
and gradual uptake into the lymph nodes where they are 
internalized by macrophages. As shown in Figure 2, SPIO 
nanoparticles allow the visualization of metastases that can 
only be vaguely discerned by conventional MRI. The sig-
niﬁ  cance of this work is that patients with localized disease 
have the option of early treatment by surgery without being 
restricted to radiation therapy, the primary treatment for 
advanced-stage patients.
Nanoparticles in drug and gene 
delivery
Among the different application areas of nanoparticles, 
drug delivery is one of the most advanced. This is large part 
due to the success of polymer- and liposome-based drug 
delivery systems (Figure 3), many of which are in clinical 
use today.
Polymer-based drug delivery systems can be categorized 
as polymeric drugs, polymer-protein conjugates, polymer-
drug conjugates, and polymeric micelles (Duncan 2003). 
Polymers can also be emulsiﬁ  ed into nanometer-size particles 
within which drugs can be trapped. Polymeric drugs are typi-
cally natural polymers that are known to have antiviral or 
antitumor characteristics. Polymer-protein conjugates most 
commonly use PEG. PEG is well known for its high water 
solubility and excellent biocompatibility, and its attachment 
to drugs results in increased solubility. PEG attachment 
is also known to reduce the renal clearance of drugs and 
enhance receptor-mediated uptake by cells. This approach 
can therefore be utilized to prolong the half life of a drug and 
reduce dosing frequency. Polymer-drug conjugation is aimed 
at improving solubility and speciﬁ  city of low molecular 
weight drugs. Lastly, polymeric micelles are typically created 
with amphipilic polymers that form micelles in solution with 
a drug entrapped inside the micelles.
Liposomes are vesicles formed by the entrapment of ﬂ  uid 
by phospholipid molecules which have hydrophobic and 
hydrophilic components and can form bilayers. A bilayer is 
formed when two layers of oriented lipid molecules come 
together such that their hydrophobic sides are in contact 
with one another. Under certain conditions, lipid molecules 
form vesicles, in which a volume of ﬂ  uid is enclosed by lipid 
bilayers. Vesicles can range in size from tens of nanometers 
to thousands of nanometers (Torchilin and Weissig 2003). 
Drug molecules can be incorporated along with the ﬂ  uid 
enclosed by vesicles or within lipid bilayers. The structure 
of these synthetic bilayers, which are biocompatible and bio-
degradable, is similar to that of biological membranes in the 
body. Targeting can be achieved by chemical modiﬁ  cation 
of the vesicle surface using ligands or polymers. As such, 
liposomes are not conventional “particles” in that they do 
not have a solid core that deﬁ  nes their identity. However, 
just like nanoscale “particles” of polymers, they are colloidal 
entities and constitute a signiﬁ  cant proportion of nanoscale 
drug delivery systems. Solid lipid nanoparticles (SLN) are 
another class of nanoparticles that are made from lipids 
that are solids at room temperature (Muller et al 2000). The 
4 mm 4 mm A B
Figure 2 Visualization of lymph node metastases in prostate cancer using iron oxide nanoparticles as MRI contrast agents. (A) A conventional MRI image can only vaguely 
indicate the presence of metastases. (B) Two metastases, indicated by arrows, can be clearly seen when the iron oxide nanoparticles are used. Scale bars = 4 mm (added 
based on the authors’ description of 2 mm metastases).  Adapted from Harisinghani et al (2003) with permission. Copyright © 2003. Massachusetts Medical Society. All 
rights reserved.International Journal of Nanomedicine 2007:2(2) 134
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nanoparticles are synthesized by emulsifying a molten lipid 
mixed with drug and surfactant which is then cooled.
The utilization of polymer- and liposome-based nanopar-
ticles in drug delivery is illustrated below with a few 
examples organized by disease type. The list of diseases 
or the number of examples within each disease is by no 
means exhaustive; the intent here is to illustrate the breath 
of nanoparticle drug delivery systems rather than cover all 
areas in depth. A summary of key examples is included in 
Table 1.
Cancer
Nanoparticles have made a tremendous impact in the 
treatment of various types of cancer, as evidenced by the 
numerous nanoparticle-based drugs and delivery systems 
that are in clinical use. Examples of numerous liposome- 
and polymer-based drugs or therapeutic agents have been 
presented in recent reviews (Duncan 2003; Allen and Cullis 
2004).
Paclitaxel is a well-known anti-cancer agent used to treat 
several types of cancer (such as ovarian, skin, esophageal, 
and lung) (Kikuchi et al 2005; Abratt et al 2006; Chao et al 
2006; De Giorgi et al 2006; Roof et al 2006; Worden et al 
2006). This drug interferes with the functions of cancer 
cells by microtubule stabilization, resulting eventually in 
apoptosis (Koziara et al 2006). The most common mode of 
administration of this water-insoluble drug is as a solution 
in ethanol (Taxol®), administered together with a solvent, 
polyoxyethylated castor oil (Cremophor® EL). A major 
shortcoming of this approach has been the side effects associ-
ated with Cremophor®, including hypersensitivity reactions, 
necessitating the administration of steroids and antihista-
mines as premedications (Zhang et al 2005a; Micha et al 
2006). In early 2005, a different form of paclitaxel known 
as Abraxane® was approved for clinical use. In this form, 
paclitaxel is loaded within nanoparticles of a natural polymer, 
albumin, using a high-pressure emulsiﬁ  cation process. This 
soluble form of paclitaxel has been shown not only to elimi-
nate the side effects associated with the use of Cremophor® 
(Micha et al 2006) but also provides some additional beneﬁ  ts. 
The albumin carrier improves transport of the drug from the 
bloodstream to the tumor site and allows higher drug dosing 
compared with Taxol® (Ibrahim et al 2002). 
Nanoparticle loading of paclitaxel, however, did not 
address multidrug resistance, a common problem in tumor 
therapy that arises when cancer cells adapt to stimuli by 
expressing efﬂ  ux transporters or other proteins on the surface 
(Gottesman et al 1996 ; Tomonaga et al 1996). Koziara and 
colleagues (2006) have attempted to overcome this problem 
by loading paclitaxel into emulsifying wax nanoparticles. 
The wax is a commercially available product (Tween 80®) 
alternatively known as polyoxyethylene 20-sorbitan mono-
oleate. The nanoparticles were prepared by heating a mixture 
of the wax, drug, and a surfactant and then emulsifying. The 
efﬁ  cacy of these drug-loaded nanoparticles was assessed in 
a murine xenograft model (HCT-15) in which tumor cells 
express p-glycoprotein, an efﬂ  ux transporter. With the help of 
a control experiment using Taxol®, the resulting cessation of 
tumor growth was judged to be due to a combination of over-
coming resistance (by nonspeciﬁ  c cytoskeletal disturbance) 
and the antiangiogenic effect of paclitaxel. These examples of 
different versions of paclitaxel serve to illustrate how differ-
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Figure 3. Schematic representations of (A) a polymeric matrix and (B) a liposome, both of which can enclose a drug. Reprinted with permission from Brigger I, Du-
bernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54:631–51 (Elsevier) and John AE, Lukacs NW, Berlin AA, et al 2003. 
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ent nanoparticle-based drug delivery strategies can be utilized 
to modulate and improve the performance of a drug.
An important consideration in tumor therapy is the 
interplay between chemotherapeutic and antiangiogenic 
agents. As Sengupta and colleagues (2005) have pointed out, 
disruption of tumor blood vessels can impact delivery of the 
chemotherapeutic agent and also cause increased expression 
of factors associated with drug resistance. These investiga-
tors synthesized a nanoparticle drug delivery system with 
two layers: a core of poly-(lactic-co-glycolic) acid (PLGA) 
conjugated with doxorubicin enclosed within a liposome 
composed of phospholipids conjugated with PEG and 
combretastatin. Here, doxorubicin is the chemotherapeutic 
agent and combretastatin is the antiangiogenic agent. These 
multilayered particles ranged in size from 80–120 nm. The 
underlying strategy was to deliver the particles to the tumor 
site and then release the drug slowly by degradation of the 
PLGA core. When administered intravenously to mice with 
tumors induced by carcinoma or melanoma cells, the par-
ticles were readily taken up by the tumor, consistent with the 
increased residence time resulting from PEG conjugation 
(Harris and Chess 2003) and the known ‘leakiness’ of tumor 
vessels (also termed the enhanced permeability and retention, 
or EPR, effect; tumor vessels have 400–600 nm pores) (Yuan 
et al 1995). The nanoparticles induced signiﬁ  cant inhibition 
of tumor growth and prolonged the lifespan of the animals.
Neurodegenerative diseases
Drug delivery to the central nervous system remains a chal-
lenge in developing effective treatments for neurodegenera-
tive diseases (Garcia-Garcia et al 2005; Popovic and Brundin 
2006). An important part of this challenge is overcoming 
the natural tendency of the blood–brain barrier (BBB) to 
block to drug transport. This barrier is designed to protect 
the brain from foreign substances and blood-borne infections 
but it cannot recognize many therapeutic compounds. As a 
result, high doses must be administered, with increased risks 
of adverse side effects. Among the different approaches 
explored in recent years to overcome this limitation are 
nanoparticle-based systems ranging from polymer particles 
to liposomes. A thorough review of work in this area has been 
published by Garcia-Garcia and colleagues (2005).
Nanoparticles made from poly(hexadecyl cyanoacrylate) 
and related compounds have been shown to facilitate drug 
transport across the BBB. Kreuter and colleagues (2003) 
adsorbed dalargin (an analgesic) onto poly(butyl cyanoac-
rylate) (PBCA) nanoparticles and demonstrated penetration 
across the BBB in rats. More recently, Siegemund and col-
leagues (2006) showed how PBCA nanoparticles loaded with 
thioﬂ  avins can target ﬁ  brillar amyloid β in a murine model 
of Alzheimer’s disease. Calvo and colleagues (2002, 2001) 
synthesized a nanoparticle system composed of a copolymer 
of PEG and poly(hexadecyl cyanoacrylate) (PHDCA). Since 
PEG is hydrophilic and PHDCA is hydrophobic, an aqueous 
environment causes the copolymer molecules to arrange 
themselves as particles with an insoluble PHDCA core and a 
surface layer of PEG. The incorporation of PEG is common 
in many drug delivery systems because it is not recognized as 
a foreign material by macrophages in blood and can therefore 
increase the half life of drug carriers in blood (Harris and 
Chess 2003). Indeed the incorporation of PEG enhances the 
ability of PHDCA to cross the BBB. Polymeric micelles 
can be formed by copolymers of PEG and materials similar 
to PEG, such as poly(propylene oxide). The commercially 
available Pluronic® P-85 polymer is an example, and P-85 
micelles have been utilized to transport analgesics across the 
BBB in mice (Witt et al 2002).
Liposome-based drug delivery systems have also been 
extensively investigated for drug delivery to the central 
nervous system (Garcia-Garcia et al 2005). Surface cover-
age with PEG is also effective in these systems. Schmidt 
and colleagues (2003) prepared liposomes with diameters 
ranging from 90–100 nm to encapsulate prednisolone, a drug 
used in the treatment of multiple sclerosis (MS). Following 
intravenous injection in mice with experimental autoimmune 
encephalomyelitis (an animal model for MS), the liposomes 
were observed to accumulate to high levels in the central 
nervous system within 2 h. Figure 4 shows gold-(black) 
labeled liposomes among astrocytes and microglia in a spinal 
cord section, indicating BBB penetration. Treatment with 
the drug-loaded liposomes resulted in restoration of BBB 
integrity and reduction in inﬂ  ammation as well as macro-
phage inﬁ  ltration. This treatment was judged to be superior 
to the administration of free glucocorticosteriods, which is 
a conventional therapy for MS.
A further application of PEG-conjugated liposomes is 
in gene delivery across the BBB. This approach is being 
followed to develop therapies for chronic neurological 
diseases that do not respond to small molecule drugs (such 
as Huntington’s disease, Rett syndrome, and Fragile-X syn-
drome, to name only a few) (Schlachetzki et al 2004). Shi 
and colleagues (2001) delivered plasmid DNA encoding 
β-galactosidase across the BBB in rats. Some of the PEG 
molecules on the liposome surfaces were attached to a target-International Journal of Nanomedicine 2007:2(2) 136
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ing monoclonal antibody anti-TFR, which targets the brain, 
liver, and spleen. Antibody attachment allowed targeted 
delivery of the liposomes to speciﬁ  c regions, and plasmid-
induced gene expression in the brain was observed for at least 
6 days following liposome administration. The signiﬁ  cance 
of this approach is the ability to transport genes that would 
normally be degraded by endonucleases in vivo by loading 
them within liposomes with targeting capability. 
HIV/AIDS
De Jaeghere and colleagues (2000) investigated the delivery 
of an HIV-1 protease inhibitor, CGP 70726, using pH-sensi-
tive nanoparticles made from a copolymer of methacrylic 
acid) and ethyl acrylate. This copolymer is commercially 
available under the name Eudragit® L100–55. The copo-
lymer was chosen because of its pH-dependent solubility. 
CGP 70726 and other similar anti-viral agents are known to 
disrupt the replication cycle of HIV-1 (Robins and Plattner 
1993). A major challenge in delivering agents such as CGP 
70726 is poor water solubility. De Jaeghere and colleagues 
synthesized nanoparticles by emulsifying a solution of the 
copolymer with a mixture of CGP 70726 and benzyl alco-
hol. The nanoparticles were administered orally to dogs and 
successful drug release was observed by analysis of blood 
samples. 
The HIV-1 Tat protein has recently emerged as a potential 
candidate for a prophylactic or therapeutic vaccine against 
HIV-1/AIDS (Cafaro et al 1999; Caputo et al 2004). Rudolph 
and colleagues (2004) recently described an SLN-based 
system consisting of DNA compacted with a Tat protein. 
This work built on earlier studies by the same group in which 
SLNs loaded with DNA were shown to transfect mammalian 
cells in vitro (Olbrich et al 2001; Tabatt et al 2004). SLNs 
were prepared from a cationic lipid in addition to a surfactant. 
DNA and Tat peptide were subsequently adsorbed onto the 
nanoparticle surface by electrostatic forces. When adminis-
tered to the lungs of mice by either intratracheal instillation or 
aerosol application, increased gene expression was observed 
indicating successful transfection of the SLNs, but some 
DNA degradation was observed. 
While there are comparatively fewer reports of in vivo 
nanoparticle-based drug delivery in the area of HIV/AIDS 
than in such areas as cancer and neurodegenerative diseases, 
activity in the area can certainly be gauged by numerous recent 
in vitro studies (Berton et al 1999, 2001; Nam et al 2002; Cui 
and Mumper 2003; Becker et al 2004; Sawant et al 2006).
Ocular diseases
The primary motivation for using nanoparticle-based drug 
delivery systems in ophthalmic applications is the ability 
to prolong drug residence times by trapping the drug in the 
ocular mucus layer (Ludwig 2005). This layer, which is 
considered to be a diffusion barrier to macromolecules, is 
secreted by goblet cells in the conjunctiva and protects the 
epithelial layer of the cornea. Most ocular diseases are treated 
with drug solutions administered as eye drops. These solu-
tions are usually highly concentrated and require frequent 
application because of rapid precorneal loss caused by the 
movement of mucus during blinking. Nanoparticles have 
provided an effective way to overcome this difﬁ  culty, as 
illustrated by a comprehensive review by Ludwig (2005); 
this review includes a summary of in vivo drug delivery 
studies in this area.
Pignatello and colleagues (2002a; 2002b) have used com-
mercially available Eudragit® polymers to deliver nonsteroi-
dal and anti-inﬂ  ammatory drugs (ﬂ  urbiprofen and ibuprofen) 
to rabbit eyes. These drugs are typically used to mitigate the 
inﬂ  ammatory response that typically occurs following oph-
thalmic surgery. The Eudragit® RS and RL polymers used in 
these investigations were copolymers of poly(ethyl acrylate), 
poly(methyl methacrylate), and poly(chlorotrimethyl-amino-
ethyl-methacrylate). These polymers are insoluble and capa-
ble of swelling under physiological conditions, making them 
suitable platforms for controlled release. Mixtures of drug 
100 μm
Figure 4 Liposome-based drug delivery to the nervous system. Gold-labeled lipo-
somes (colored black in image) among astrocytes and microglia in rat spinal cord 
sections indicating penetration of the blood–brain barrier (astrocytes and microglia 
stained red); scale bar = 100 μm.  Adapted from Schmidt et al (2003) by permission 
of Oxford University Press.International Journal of Nanomedicine 2007:2(2) 137
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and polymer were dissolved in ethanol and emulsiﬁ  ed (with 
the help of water and a surfactant) to form drug-embedded 
nanoparticles ~100 nm in size. Saline suspensions of these 
nanoparticles were instilled in the conjunctive sac of the rab-
bit eyes. Nanoparticles loaded with both drugs (ﬂ  urbiprofen 
and ibuprofen) effectively inhibited inﬂ  ammatory responses 
after surgical trauma and were comparable with conventional 
eye-drop controls. The signiﬁ  cance of this result is that the 
nanoparticle system was assembled with a lower drug con-
centration compared to the eye-drop control. Secondly the 
nanoparticle system was able to generate higher drug levels 
in the vitreous humor, which arises from the longer residence 
time of the drug in the polymer matrix.
Certain disease conditions, such as cytomegalovirus 
(CMV) retinitis require administration of drugs to the retinal 
region of the eye. Infection with CMV can lead to permanent 
damage of the retina, choroid (the region behind the retina), 
iris, and adjacent tissue. Merodio and colleagues (2002) 
have described the use of bovine serum albumin (BSA) 
nanoparticles to deliver ganciclovir, a drug used to treat CMV 
infection. The drug was incubated with BSA in an aqueous 
solution and droplets were subsequently generated by the ad-
ditional of ethanol in an emulsiﬁ  cation process; the resulting 
nanoparticles were approximately 280 nm in diameter. These 
nanoparticles were resuspended in saline and administered by 
intravitreal injection. The authors observed that the nanopar-
ticles remained in a thin layer on the retina for up to two 
weeks post-injection and histological analysis indicated the 
absence of any inﬂ  ammatory responses or changes in tissue 
morphology compared with normal eye controls.
Respiratory diseases
The application of nanoparticle-based drug delivery 
approaches in respiratory diseases has been somewhat 
limited. The literature nevertheless contains several examples 
of therapies that have been effectively demonstrated for the 
treatment of allergic, genetic, and infections diseases of the 
respiratory system (Pison et al 2006). 
John and colleagues (2003) demonstrated the use of a 
liposome-based nanoparticle system to inhibit inﬂ  amma-
tion in a murine model of allergic asthma. The strategy 
employed was to inhibit P-selectin receptors on activated 
endothelial cells in circulation, which mitigates interactions 
between endothelial cells and leukocytes. This, in turn, 
attenuates the development of peribronchial inﬂ  ammation. 
The nanoparticles (average diameter of 73 nm) were designed 
to mimic the physiological P-selectin super ligand (PSGL-1) 
by incorporating fucose and sulfate ester groups on the lipo-
some surface. Lung inﬂ  ammation and airway hyperreactivity 
were induced in mice by LPS and cockroach antigen. In 
both instances, the liposomal nanoparticles were observed 
to bind preferentially to selectins on activated endothelial 
cells (Figure 5). Histological analysis indicated signiﬁ  cant 
reduction in peribronchial inﬂ  ammation and airway hyper-
reactivity in mice treated with the nanoparticles compared 
with controls.
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Figure 5 Selective binding of liposomes presenting fucose and sulfate ester groups to activated endothelial cells in mouse lungs following allergen challenge. (A) Nega-
tive control (liposomes without fucose and sulfate ester groups). (B) Liposomes with fucose and sulfate ester groups. Scale bars in both images = 30 μm.  Adapted with 
permission from John et al (2003).
Abbreviations: alv, alveolar wall; bv, blood vessel; e, endothelium; PLNP, liposomes.International Journal of Nanomedicine 2007:2(2) 138
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Kumar and colleagues (2003) have described how 
a polymer-drug conjugate, chitosan/interferon-γ pDNA 
nanoparticles, can reduce allergen-induced airway inﬂ  am-
mation. It is known that allergic diseases (such as asthma) 
cause a drop in production of interferon-γ (IFN-γ) in patients, 
leaving the patients susceptible to airway inﬂ  ammation and 
hyperresponsiveness. The approach of Kumar and colleagues 
(2003) aims to overcome IFN-γ deﬁ  ciency by supplying it 
intranasally as a polymer-drug conjugate. In allergen-chal-
lenged mice, nanoparticle therapy resulted in increased IFN-γ 
expression by epithelial cells, thereby facilitating reduction 
in inﬂ  ammation and restoration of lung morphology within 
3–6 hours. 
Environmental and societal 
considerations
The impact of nanomaterials on the environment and on 
public health has received considerable attention in recent 
years. As technologies in nanomedicine and the broader ﬁ  eld 
of nanotechnology mature, however, much more needs to be 
done, particularly because different nanomaterials have dif-
ferent kinds of risks associated with them. This section will 
focus on the nanoparticle types described in the applications 
above. As in the previous sections, in vivo studies will be 
given particular attention; however signiﬁ  cant in vitro work 
will also be described. 
Toxicity of quantum dots
As described in the section on medical imaging, QDs are 
inorganic nanoparticles that typically have an organic coat-
ing them makes them biocompatible or bioactive. The main 
toxicological risk associated with the use of QDs in vivo is the 
exposure of the inorganic core by deterioration of the organic 
layer. QDs can be made from a large variety of inorganic-
metal complexes, such as CdSe, ZnS, CdTe, InP, InAs, GaAs, 
to name only a few. Each such compound has unique chemi-
cal properties that can profoundly inﬂ  uence its toxicology. 
Although the literature on the toxicity of such compounds in 
vivo is not extensive, there are reports that highlight major 
concerns and illustrate the need for more work. A detailed 
review of the toxicology of quantum dots was recently pub-
lished by Hardman (2006). A summary of recent toxicogical 
investigations on QDs is given in Table 2.
Derfus and colleagues (2004) examined the toxicity of a 
range of cadmium-based QDs using an in vitro model consist-
ing of primary rat hepatocytes. The choice of this cell type was 
motivated by the fact that the liver is the primary target of Cd 
exposure. QDs with CdSe cores capped with mercaptoacetic 
acid (MAA) and TOPO were determined to be acutely cyto-
toxic at a QD concentration of 62.5 μg/mL. This behavior was 
correlated with the liberation of Cd2+ ions following oxidation 
of the CdSe lattice by air and ultraviolet (UV) light. Surface 
oxidation and cytotoxicity were nearly eliminated by coating 
the CdSe particles with ZnS and further improvement was 
observed by polymer or protein coating on top of the ZnS. 
While this was an encouraging result, some Cd release was 
also observed from commercial QDs made with CdSe/ZnS 
with an overcoat of polyacrylate and streptavidin. 
Ballou and colleagues (2004) examined the in vivo toxicity 
of CdSe/ZnS QDs coated with either amphiphilic poly(acrylic 
acid) or PEG in mice. QDs were administered to the animals at 
a concentration of 20 pmol/g animal weight. No necrosis was 
Table 2 Toxicological effects of nanoparticles associated with medical applications
Nanoparticle type  Toxicological effects  References
Quantum dots  Potential for exposure to inorganic core (eg, cadmium) and   Derfus et al  2004
  resulting cytotoxic effects (eg, liver damage).
  Toxicity risk greatly reduced by coating with ZnS and soluble polymers (such as PEG).  Ballou et al 2004
  Risks associated with production, handling, and storage of QDs need to be evaluated.  Oberdorster et al 2005;  
   Hardman 2006
Metallic  Iron oxide and gold nanoparticles are not toxic.  Weissleder et al 1989;  
   Connor et al 2005; 
   Muldoon et al 2005; 
   Hainfeld et al 2006;.
  Surface functionalization may inﬂ  uence toxicity.  Goodman et al 2004
Polymeric/liposomal   Not toxic since these nanoparticles have natural or highly biocompatible 
  components (eg, chitosan, PEG).  Alonso 2004;  
   de Campos et al 2004
Abbreviations: PEG, poly(ethylene glycol); QD, quantum dots. International Journal of Nanomedicine 2007:2(2) 139
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observed in liver, spleen, and bone marrow, where the QDs 
were observed to deposit, and the animals remained viable 
for 133 days when tissue analysis was performed.
The above two examples illustrate the complexities of 
measuring the toxicity of QDs. The in vitro and in vivo 
studies cannot be directly compared because of inherent dif-
ferences in experimental design (QD concentration measure-
ment being just one of many aspects of this) and differences 
in the organic coating. Nevertheless, they point to the need 
for long-term animal studies before QDs can be approved 
for commercial use; they also point to the potential need for 
controlled conditions in storing and handling QDs. Questions 
that arise with regard to the safety of QD manufacturing 
processes, such as the risk of QD exposure by inhalation 
or dermal contact, also need to be answered deﬁ  nitively 
(Oberdorster et al 2005; Hardman 2006). 
Toxicity of metallic nanoparticles
Muldoon and colleagues (2005) investigated the toxicity of 
superparamagnetic iron oxide nanoparticles used as MRI 
contrast agents in rats. The nanoparticles were administered 
to the brain by either intracerebral inoculation or intraarteri-
ally. Although the MRI signal intensity dropped over time 
(weeks to months), no pathological changes were observed 
in brain tissue in normal rats. These ﬁ  ndings are consistent 
with a toxicity study of iron oxide nanoparticles in mice 
and dogs performed nearly two decades ago by Weissleder 
and colleagues (1989). In this work, the nanoparticles were 
administered intravenously and no acute or subacute toxicity 
responses were found in the histology of targeted tissues or in 
blood tests. The safety of various iron oxide-based nanoparti-
cles used as contrast agents in clinical use is well-established 
(Lubbe et al 1999, 2001; Neuberger et al 2005).
Hainfeld and colleagues (2006) examined the toxicity of 
gold nanoparticles within the context of their use as X-ray 
contrast agents. When injected intravenously into mice, 
accumulation was observed in kidneys and within tumors 
(retention was low in the liver and spleen). Organ histology 
and blood analysis did not show any indication of toxicity 
up to 30 days following injection. These observations are 
consistent with the ﬁ  ndings from an in vitro study of gold 
nanoparticle toxicity performed by Connor and colleagues 
(2005) with a human leukemia cell line. 
The nanoparticles were taken up by the cells but did not 
cause cytotoxicity. The chemical surface modiﬁ  cation of 
gold nanoparticles can, however, impact toxicity. Goodman 
and colleagues (2004) recently demonstrated that attachment 
of a cationic polymer monolayer (alkyl thiol with a quater-
nary ammonium group) onto gold nanoparticles can render 
them cytotoxic. Attachment of an anionic monolayer (alkyl 
chain with carboxylate end group), however did not result 
in cytotoxic behavior.
Toxicity of polymeric and liposomal 
nanoparticles
This category of nanoparticles is probably the least problem-
atic with respect to toxicity because the particles are very 
often typically either made from or covered with natural 
or highly biocompatible polymers (such as PEG). In drug 
delivery applications, these particles often carry drugs that 
are cytotoxic by design (to kill cancer cells) but they are 
prevented from attacking other regions of the body by the 
selective targeting described earlier in this review.
The incorporation of natural polymers such as chitosan 
or natural lipids in the assembly of polymer- or liposome-
based nanoparticles is beneﬁ  cial because these polymers are 
not recognized as being foreign by the body and are readily 
metabolized (Alonso 2004; de Campos et al 2004). Nanopar-
ticles made from synthetic polymers can vary widely in the 
rate of clearance from the blood stream and accumulation 
in mononuclear phagocytic system (MPS) organs (MPS) 
organs (such as the liver and spleen) depending on polymer 
type and composition (Moghimi et al 2001; Owens and 
Peppas 2006). The incorporation of PEG in the nanoparticle 
structure can delay the removal of nanoparticles from the 
blood stream, as discussed earlier. PEG-coated particles are 
therefore considered to be less toxic than uncoated particles 
because they are less likely to saturate the MPS (Peracchia 
et al 1999; Plard and Bazile 1999).
Summary
Nanoparticles have made major contributions to clinical 
medicine in the areas of medical imaging and drug/gene 
delivery. While several innovations such as iron oxide 
contrast agents and many drug delivery systems are by now 
well-established, newer technologies continue to emerge 
following the same basic concepts of design. As these 
innovations advance to clinical application, attention must be 
paid to environmental and societal implications, particularly 
in areas such as quantum dots.
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